Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra
- PMID: 18577498
- DOI: 10.1016/j.expneurol.2008.05.006
Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra
Abstract
Ghrelin, a stomach-derived hormone which induces growth hormone release and promotes positive energy balance, has been reported to inhibit cell apoptosis in endotheliocytes, osteoblasts and cardiocytes. Recent evidence has shown that ghrelin can also inhibit neuronal apoptosis of the hypothalamus and the hippocampus. However, little is known about the effects of ghrelin on the substantia nigra pars compacta (SNpc) neurons in which ghrelin's receptor, growth hormone secretagogue receptor (GHSR)-1a, is highly expressed. In the present study, we investigated whether ghrelin could protect nigral dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice. We observed that ghrelin, acting through GHS-R 1a, inhibited MPTP-induced dopaminergic neuronal loss in the SNpc as well as dopamine depletion in the striatum. Ghrelin could also reverse the down-regulated the expression of Bcl-2, up-regulated the expression of Bax, and caspase-3 activation caused by MPTP. This study demonstrated that ghrelin might be a potential protector of dopaminergic neurons in a therapeutic strategy for Parkinson's disease.
Similar articles
-
CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.J Pharmacol Exp Ther. 1999 Feb;288(2):421-7. J Pharmacol Exp Ther. 1999. PMID: 9918541
-
Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.Neurosci Res. 2008 Feb;60(2):156-61. doi: 10.1016/j.neures.2007.10.005. Epub 2007 Oct 23. Neurosci Res. 2008. PMID: 18054104
-
Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.Neurotox Res. 2009 May;15(4):332-47. doi: 10.1007/s12640-009-9037-x. Epub 2009 Mar 17. Neurotox Res. 2009. PMID: 19384567
-
Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.Med Sci Monit. 2005 Jan;11(1):RA17-23. Med Sci Monit. 2005. PMID: 15614202 Review.
-
Inflammation in Parkinson's disease: causative or epiphenomenal?Subcell Biochem. 2007;42:249-79. Subcell Biochem. 2007. PMID: 17612055 Review.
Cited by
-
Ghrelin protects spinal cord motoneurons against chronic glutamate excitotoxicity by inhibiting microglial activation.Korean J Physiol Pharmacol. 2012 Feb;16(1):43-8. doi: 10.4196/kjpp.2012.16.1.43. Epub 2012 Feb 28. Korean J Physiol Pharmacol. 2012. PMID: 22416219 Free PMC article.
-
The Emerging Role of Neuropeptides in Parkinson's Disease.Front Aging Neurosci. 2021 Mar 8;13:646726. doi: 10.3389/fnagi.2021.646726. eCollection 2021. Front Aging Neurosci. 2021. PMID: 33762925 Free PMC article. Review.
-
Recombinant adenovirus-mediated expression of GHS-R1a in HEK 293 cells.Neurosci Bull. 2010 Jun;26(3):225-31. doi: 10.1007/s12264-010-1228-1. Neurosci Bull. 2010. PMID: 20502502 Free PMC article.
-
Ghrelin inhibits oligodendrocyte cell death by attenuating microglial activation.Endocrinol Metab (Seoul). 2014 Sep;29(3):371-8. doi: 10.3803/EnM.2014.29.3.371. Epub 2014 Sep 25. Endocrinol Metab (Seoul). 2014. PMID: 25309797 Free PMC article.
-
Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats.Neurogastroenterol Motil. 2012 May;24(5):e235-45. doi: 10.1111/j.1365-2982.2012.01904.x. Epub 2012 Mar 23. Neurogastroenterol Motil. 2012. PMID: 22443313 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous